Evidence map›Paper›PMID 38321740›Full record

ArticleBiophysical journal2024

Antibody surface mobility amplifies FcγR signaling via Arp2/3 during phagocytosis.

Seongwan Jo, Brady R Fischer, Nicholas M Cronin, Ni Putu Dewi Nurmalasari, Yoseph M Loyd, Jason G Kerkvliet, Elizabeth M Bailey, Robert B Anderson, Brandon L Scott, Adam D Hoppe

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Biophysics of immune cell signaling.Biophysical journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Seongwan JoDepartment of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota; BioSNTRii, South Dakota State University, Brookings, South Dakota.
Brady R FischerDepartment of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota; BioSNTRii, South Dakota State University, Brookings, South Dakota.
Nicholas M CroninDepartment of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota; BioSNTRii, South Dakota State University, Brookings, South Dakota.
Ni Putu Dewi NurmalasariDepartment of Nanoscience & Biomedical Engineering, South Dakota School of Mines and Technology, Rapid City, South Dakota; BioSNTRii, South Dakota School of Mines and Technology, Rapid City, South Dakota.
Yoseph M LoydDepartment of Nanoscience & Biomedical Engineering, South Dakota School of Mines and Technology, Rapid City, South Dakota; BioSNTRii, South Dakota School of Mines and Technology, Rapid City, South Dakota.
Jason G KerkvlietDepartment of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota; BioSNTRii, South Dakota State University, Brookings, South Dakota.
Elizabeth M BaileyDepartment of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota; BioSNTRii, South Dakota State University, Brookings, South Dakota.
Robert B AndersonDepartment of Nanoscience & Biomedical Engineering, South Dakota School of Mines and Technology, Rapid City, South Dakota; BioSNTRii, South Dakota School of Mines and Technology, Rapid City, South Dakota.
Brandon L ScottDepartment of Nanoscience & Biomedical Engineering, South Dakota School of Mines and Technology, Rapid City, South Dakota; BioSNTRii, South Dakota School of Mines and Technology, Rapid City, South Dakota.
Adam D HoppeDepartment of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota; BioSNTRii, South Dakota State University, Brookings, South Dakota. Electronic address: adam.hoppe@sdstate.edu.
South Dakota State University · USSouth Dakota School of Mines and Technology · US

Funding

Transcriptome & Networks Analysis CoreP20GM135008 · NIGMS · SOUTH DAKOTA STATE UNIVERSITY · PI Adam David Hoppe · 2022 to 2026
$13.5M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
The immune regulation of macrophage antibody dependent cellular phagocytosisU01AI148153 · NIAID · SOUTH DAKOTA STATE UNIVERSITY · PI HOPPE, ADAM DAVID · 2020 to 2024
$1.9M
NIAID NIH HHS U01 AI148153NIGMS NIH HHS P20 GM135008NIGMS NIH HHS R01 GM129325
6 · The paper itself

Abstract

We report herein that the anti-CD20 therapeutic antibody, rituximab, is rearranged into microclusters within the phagocytic synapse by macrophage Fcγ receptors (FcγR) during antibody-dependent cellular phagocytosis. These microclusters were observed to potently recruit Syk and to undergo rearrangements that were limited by the cytoskeleton of the target cell, with depolymerization of target-cell actin filaments leading to modest increases in phagocytic efficiency. Total internal reflection fluorescence analysis revealed that FcγR total phosphorylation, Syk phosphorylation, and Syk recruitment were enhanced when IgG-FcγR microclustering was enabled on fluid bilayers relative to immobile bilayers in a process that required Arp2/3. We conclude that on fluid surfaces, IgG-FcγR microclustering promotes signaling through Syk that is amplified by Arp2/3-driven actin rearrangements. Thus, the surface mobility of antigens bound by IgG shapes the signaling of FcγR with an unrecognized complexity beyond the zipper and trigger models of phagocytosis.

Indexed as

Actin-Related Protein 2-3 ComplexPhagocytosisReceptors, IgGSignal TransductionSyk KinaseAnimalsHumansImmunoglobulin GMicePhosphorylationRituximabActin-Related Protein 2-3 ComplexImmunoglobulin GReceptors, IgGRituximabSyk Kinase

Identifiers

PMID38321740
PMCPMC11331046
OpenAlexW4391541977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.